MX2019002288A - Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores. - Google Patents

Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.

Info

Publication number
MX2019002288A
MX2019002288A MX2019002288A MX2019002288A MX2019002288A MX 2019002288 A MX2019002288 A MX 2019002288A MX 2019002288 A MX2019002288 A MX 2019002288A MX 2019002288 A MX2019002288 A MX 2019002288A MX 2019002288 A MX2019002288 A MX 2019002288A
Authority
MX
Mexico
Prior art keywords
cell suspension
treatment
artery disease
lower extremity
peripheral artery
Prior art date
Application number
MX2019002288A
Other languages
English (en)
Inventor
Robert Barclay Dupere Jonathan
De Jong Llesbeth
J Wagena Edwin
Original Assignee
Rexgenero Biosciences S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexgenero Biosciences S L filed Critical Rexgenero Biosciences S L
Publication of MX2019002288A publication Critical patent/MX2019002288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La presente invención se refiere a una suspensión celular de glóbulos blancos derivados de médula ósea de adulto, autólogos o alogénicos, preferiblemente autólogos, preferiblemente derivados de la cresta del íleon (o cresta ilíaca), enriquecida por células mononucleares, lo que significa que más del 25% de los glóbulos blancos (WBC) presentes en la suspensión celular son células mononucleares, y que comprende: A. Células mononucleares (MNC) seleccionadas de la lista que comprende o que consiste en: i. una población de linfocitos; ii. una población de monocitos; y iii. una población de células madre hematopoyéticas que expresan CD34; y en la que la suspensión celular comprende, además: B. granulocitos; para su uso en el tratamiento o la mejora de la arteriopatía periférica de las extremidades inferiores.
MX2019002288A 2016-08-26 2017-08-28 Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores. MX2019002288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382405 2016-08-26
PCT/EP2017/071580 WO2018037134A1 (en) 2016-08-26 2017-08-28 Cell suspension for use in the treatment of lower extremity peripheral artery disease

Publications (1)

Publication Number Publication Date
MX2019002288A true MX2019002288A (es) 2019-09-18

Family

ID=56842774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002288A MX2019002288A (es) 2016-08-26 2017-08-28 Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.

Country Status (14)

Country Link
US (2) US10869886B2 (es)
EP (1) EP3504322A1 (es)
JP (2) JP7260878B2 (es)
KR (1) KR20190053198A (es)
CN (1) CN110168077A (es)
AU (1) AU2017315174B2 (es)
BR (1) BR112019003543A2 (es)
CA (1) CA3035076A1 (es)
EA (1) EA201990583A1 (es)
MX (1) MX2019002288A (es)
SA (1) SA519401187B1 (es)
SG (1) SG11201901594RA (es)
WO (1) WO2018037134A1 (es)
ZA (1) ZA201901826B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
US9463036B2 (en) 2010-10-22 2016-10-11 Neuravi Limited Clot engagement and removal system
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
SG11201901594RA (en) * 2016-08-26 2019-03-28 Rexgenero Biosciences S L Cell suspension for use in the treatment of lower extremity peripheral artery disease
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
CN114561352A (zh) * 2022-03-24 2022-05-31 青岛市中心血站 从无偿献血全血采集装置中分离单个核细胞的方法
WO2024099865A1 (en) * 2022-11-08 2024-05-16 Servicio Andaluz De Salud Cell suspension for use in the treatment of stroke patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
EP2331679B1 (en) * 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
US20150157663A1 (en) * 2012-01-19 2015-06-11 Snu R&Db Foundation Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass
EP2817014A2 (en) * 2012-02-21 2014-12-31 Baxter International Inc Pharmaceutical composition comprising cd34+ cells
SG11201901594RA (en) * 2016-08-26 2019-03-28 Rexgenero Biosciences S L Cell suspension for use in the treatment of lower extremity peripheral artery disease

Also Published As

Publication number Publication date
AU2017315174B2 (en) 2023-11-09
US20180055884A1 (en) 2018-03-01
AU2017315174A1 (en) 2019-04-18
CA3035076A1 (en) 2018-03-01
CN110168077A (zh) 2019-08-23
JP7260878B2 (ja) 2023-04-19
SA519401187B1 (ar) 2023-01-09
ZA201901826B (en) 2019-12-18
US20210161960A1 (en) 2021-06-03
EP3504322A1 (en) 2019-07-03
EA201990583A1 (ru) 2019-08-30
US10869886B2 (en) 2020-12-22
WO2018037134A1 (en) 2018-03-01
BR112019003543A2 (pt) 2019-05-21
JP2019528325A (ja) 2019-10-10
JP2022166251A (ja) 2022-11-01
SG11201901594RA (en) 2019-03-28
KR20190053198A (ko) 2019-05-17

Similar Documents

Publication Publication Date Title
MX2019002288A (es) Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.
Pierdomenico et al. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp
Vallone et al. Mesenchymal stem cells and their use in therapy: what has been achieved?
MY155137A (en) Compounds that expand hematopoietic stem cells
MX2019005127A (es) Poblaciones y productos de células madre mesenquimales y sus usos.
Blanco et al. Immunomodulatory effects of bone marrow versus adipose tissue‐derived mesenchymal stromal cells on NK cells: Implications in the transplantation setting
WO2007140472A3 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
MX2023007726A (es) Antifolatos poliglutamados alfa y gamma-d y sus usos.
ZA200500682B (en) Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
MX345730B (es) Células adherentes derivadas del amnios (amdac) para usarse en el tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario.
EP2548950A3 (en) Reprogramming T cells and hematopoietic cells
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
MX2013004061A (es) Analogos de ciclosporina.
Wu et al. Serum-free media and the immunoregulatory properties of mesenchymal stem cells in vivo and in vitro
MX2013004062A (es) Analogos de ciclosporina.
WO2006102209A3 (en) Cd34(+) cells and their methods of use
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
EA201790883A1 (ru) Толерогенные дендритные клетки, способы их получения и их применения
Tournois et al. Cell therapy in critical limb ischemia: a comprehensive analysis of two cell therapy products
SG11201900796UA (en) Prophylactic or therapeutic agent for vascular disorder
GB2530224A (en) Enhancement of osteogenic potential of bone grafts